CO6571868A2 - Procedimiento para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico - Google Patents

Procedimiento para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico

Info

Publication number
CO6571868A2
CO6571868A2 CO12170407A CO12170407A CO6571868A2 CO 6571868 A2 CO6571868 A2 CO 6571868A2 CO 12170407 A CO12170407 A CO 12170407A CO 12170407 A CO12170407 A CO 12170407A CO 6571868 A2 CO6571868 A2 CO 6571868A2
Authority
CO
Colombia
Prior art keywords
proteasome inhibitors
procedure
formation
cyclodextrin complexes
peptide proteasome
Prior art date
Application number
CO12170407A
Other languages
English (en)
Inventor
Evan Lewis
Peter Shwonek
M Sean Dalziel
Mouhannad Jumaa
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49549072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6571868(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of CO6571868A2 publication Critical patent/CO6571868A2/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente divulgación proporciona procedimientos para formular composiciones que comprenden uno o más inhibidores del proteasoma peptídico y una ciclodextrina, en particular una ciclodextrina sustituida. Dichos procedimientos incrementan considerablemente la solubilidad y la estabilidad de estos inhibidores del proteasoma y facilitan tanto su fabricación como su administración.
CO12170407A 2012-05-08 2012-09-28 Procedimiento para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico CO6571868A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261644122P 2012-05-08 2012-05-08

Publications (1)

Publication Number Publication Date
CO6571868A2 true CO6571868A2 (es) 2012-11-30

Family

ID=49549072

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12170407A CO6571868A2 (es) 2012-05-08 2012-09-28 Procedimiento para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico

Country Status (21)

Country Link
US (2) US20130303465A1 (es)
JP (1) JP2015516416A (es)
KR (1) KR20150007361A (es)
CN (1) CN103781490A (es)
AR (2) AR087863A1 (es)
AU (1) AU2012238318B2 (es)
BR (1) BR112012028726B1 (es)
CA (1) CA2793894A1 (es)
CO (1) CO6571868A2 (es)
CR (1) CR20120485A (es)
CU (1) CU20120159A7 (es)
DO (1) DOP2012000252A (es)
EA (1) EA201201519A1 (es)
EC (1) ECSP12012167A (es)
MA (1) MA35238B1 (es)
MX (1) MX2012010891A (es)
MY (2) MY196510A (es)
SG (1) SG194417A1 (es)
TW (1) TWI603737B (es)
WO (1) WO2013169282A1 (es)
ZA (1) ZA201207384B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
DK2814849T3 (da) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
DK2970225T3 (en) 2013-03-14 2018-09-24 Onyx Therapeutics Inc DIPEPTIDE AND TRIPEPTIDE AS EPOXY-KETONE PROTEASE INHIBITORS
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
WO2015009888A2 (en) 2013-07-19 2015-01-22 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
CN104945470B (zh) * 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
CN103936828A (zh) * 2014-05-12 2014-07-23 苏州科耐尔医药科技有限公司 卡非佐米中间体及卡非佐米的制备方法
CN105919972A (zh) * 2015-12-18 2016-09-07 重庆两江药物研发中心有限公司 一种包载卡非佐米的纳米粒制剂及其制备方法
TWI759301B (zh) * 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
UA125648C2 (uk) 2016-08-05 2022-05-11 Емджен Інк. Синтез (s)-2-аміно-4-метил-1-((r)-2-метилоксиран-2-іл)-пентан-1-ону та його фармацевтично прийнятних солей
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
US20180282260A1 (en) * 2017-03-31 2018-10-04 Valent Biosciences Llc 1-aminocyclopropane-1-carboxylic acid polymorphs
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
CN111344018A (zh) 2017-11-16 2020-06-26 美国安进公司 聚乙二醇化卡非佐米化合物的稳定的组合物
EP3716948B1 (en) * 2017-11-30 2023-11-22 Cytogel Pharma, LLC Novel analgesic pharmaceutical formulations and uses thereof
AU2021292417A1 (en) * 2020-06-19 2023-01-19 Amgen Inc. Methods of measuring carfilzomib
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE499109T1 (de) * 2004-12-07 2011-03-15 Proteolix Inc Zusammensetzung zur proteasomhemmung
KR101274417B1 (ko) * 2005-11-09 2013-06-17 프로테올릭스, 인코퍼레이티드 효소 저해를 위한 화합물
MY173938A (en) * 2007-10-04 2020-02-27 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides

Also Published As

Publication number Publication date
SG194417A1 (en) 2013-12-30
MA35238B1 (fr) 2014-07-03
EA201201519A1 (ru) 2013-11-29
AR087863A1 (es) 2014-04-23
AU2012238318A1 (en) 2013-11-28
AR127861A2 (es) 2024-03-06
TW201345543A (zh) 2013-11-16
ECSP12012167A (es) 2013-02-28
CN103781490A (zh) 2014-05-07
US20130303465A1 (en) 2013-11-14
MY196510A (en) 2023-04-18
BR112012028726A2 (pt) 2016-07-19
MY165002A (en) 2018-02-28
BR112012028726B1 (pt) 2021-07-13
ZA201207384B (en) 2018-12-19
WO2013169282A1 (en) 2013-11-14
US20130303482A1 (en) 2013-11-14
CR20120485A (es) 2013-12-18
NZ602490A (en) 2016-03-31
KR20150007361A (ko) 2015-01-21
CU20120159A7 (es) 2014-03-26
MX2012010891A (es) 2014-03-05
DOP2012000252A (es) 2013-12-31
JP2015516416A (ja) 2015-06-11
AU2012238318B2 (en) 2014-02-13
TWI603737B (zh) 2017-11-01
CA2793894A1 (en) 2013-11-08

Similar Documents

Publication Publication Date Title
CO6571868A2 (es) Procedimiento para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico
CL2017000969A1 (es) Composiciones del factor viii y métodos para hacerlas y usarlas (divisional solicitud no. 2166-2014)
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
GT201500051A (es) Inhibidores de glucosilceramida sintasa
CR20170352A (es) Terapias de combinación para el tratamiento de cánceres
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
BR112016012146A8 (pt) derivados de aminopiridina como inibidores de quinase da família tam
CR20120529A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CR20150250A (es) Nuevos derivados de piridina
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
CO7151512A2 (es) Inhibidores del nampt
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
TR201909447T4 (tr) Aramkol tuzları.
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
UY34078A (es) Composiciones farmacéuticas y métodos para tratar el cáncer
MX2015013255A (es) Metodos para tratar cancer colorrectal.
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
UY34829A (es) Nueva dosificación y formulación
MX358132B (es) Solucion de trombina y metodos de uso de esta.
MX2015016603A (es) Composiciones de corticosteroides.
BR112015030135A2 (pt) ésteres de ácidos oligo-hidróxi carboxílicos e seu uso
BR112014019220A8 (pt) Novos derivados de pirrolidina
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
BR112013027390A2 (pt) formulação farmacêutica

Legal Events

Date Code Title Description
FC Application refused